AbbVie (ABBV) analysis

Loading the Vaultflake…

Health is the cash after what Humira no longer contributes, not an assured dividend. Quality separates Skyrizi and Rinvoq from the old sale. Growth follows whatever replaces the lost exclusivity, not the old portfolio. P/E is read against a year in which the newer medicine grows, not against that year as normal. Shareholder return is the dividend, checked against that cash. Do not call it a returns machine.

The P/E of a Humira year is not the earnings after. EV/EBITDA is read without treating Skyrizi as if it had already replaced the whole old sale. Do not use Regeneron's multiple as if Dupixent and these two brands were the same book. A dash if the ABBV cache is cold.

Limits of this report

Not advice on AbbVie. Vaultflake does not state what is left of Humira or treat the dividend as safe. Read the filings. A past dividend is not a right. The table is a snapshot, not a target price.

Questions from this report